These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32441114)

  • 21. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
    Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis.
    Rodrigo GJ; Castro-Rodriguez JA; Nannini LJ; Plaza Moral V; Schiavi EA
    Respir Med; 2009 Oct; 103(10):1421-9. PubMed ID: 19556116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2008 Sep; 300(12):1439-50. PubMed ID: 18812535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Brennan JM; Wruck L; Pencina MJ; Clare RM; Lopes RD; Alexander JH; O'Brien S; Krucoff M; Rao SV; Wang TY; Curtis LH; Newby LK; Granger CB; Patel M; Mahaffey K; Ross JS; Normand SL; Eloff BC; Caños DA; Lokhnygina YV; Roe MT; Califf RM; Marinac-Dabic D; Peterson ED
    Am Heart J; 2019 Dec; 218():110-122. PubMed ID: 31726314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
    McGarvey L; Niewoehner D; Magder S; Sachs P; Tetzlaff K; Hamilton A; Korducki L; Bothner U; Vogelmeier C; Koch A; Ferguson GT
    COPD; 2015; 12(5):484-93. PubMed ID: 25692310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.
    Dransfield MT; McAllister DA; Anderson JA; Brook RD; Calverley PMA; Celli BR; Crim C; Gallot N; Martinez FJ; Scanlon PD; Yates J; Vestbo J; Newby DE;
    Ann Am Thorac Soc; 2018 May; 15(5):608-614. PubMed ID: 29406772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.
    Bakerly ND; Woodcock A; New JP; Gibson JM; Wu W; Leather D; Vestbo J
    Respir Res; 2015 Sep; 16(1):101. PubMed ID: 26337978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
    Vestbo J; Leather D; Diar Bakerly N; New J; Gibson JM; McCorkindale S; Collier S; Crawford J; Frith L; Harvey C; Svedsater H; Woodcock A;
    N Engl J Med; 2016 Sep; 375(13):1253-60. PubMed ID: 27593504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost analysis of COPD exacerbations and cardiovascular events in SUMMIT.
    Stanford RH; Coutinho AD; Eaddy M; Yue B; Bogart M
    Am J Manag Care; 2019 Nov; 25(11):e320-e325. PubMed ID: 31747236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR; Kaelin T; Richard N; Zvarich M; Church A
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Serebruany VL; Atar D
    Thromb Haemost; 2012 Sep; 108(3):412-4. PubMed ID: 22836596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial.
    Bolland MJ; Barber A; Doughty RN; Grey A; Gamble G; Reid IR
    BMJ Open; 2013 Mar; 3(3):. PubMed ID: 23512838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study.
    Chen YF; Cheng YC; Chou CH; Chen CY; Yu CJ
    BMC Pulm Med; 2019 Dec; 19(1):233. PubMed ID: 31795986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 38. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
    Raparelli V; Pastori D; Pignataro SF; Vestri AR; Pignatelli P; Cangemi R; Proietti M; Davì G; Hiatt WR; Lip GYH; Corazza GR; Perticone F; Violi F; Basili S;
    Intern Emerg Med; 2018 Aug; 13(5):651-660. PubMed ID: 29582316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.
    Pogue J; Walter SD; Yusuf S
    Clin Trials; 2009 Jun; 6(3):239-51. PubMed ID: 19528133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.
    Hoogwerf BJ; Lincoff AM; Rodriguez A; Chen L; Qu Y
    Cardiovasc Diabetol; 2016 May; 15():78. PubMed ID: 27188479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.